AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

GOSERELINE

9 registrations across 4 African markets— 6 active

Markets with GOSERELINE

Recent registrations

Brand / ProductMarketHolderStatusExpires
ZOLADEX 10,8MG IMPLANT EB SERINGUE PREREMPLIE POUR VOIE SOUS-CUTANEE+SYSTEME DE SECURITE BOITE DE 1🇨🇮Côte d'IvoireASTRAZENECAactiveAug 2027
ZOLADEX 3,6MG IMPLANT EN SERINGUE PREREMPLIE EN SC BOITE DE 1🇨🇮Côte d'IvoireASTRAZENECAactiveAug 2026
GOSERELIN-CIMEX
Implant / 3.6 mg
🇹🇳TunisiaACINO pharma AGexpiredMay 2013
ZOLADEX
Implant / 10.8 MG
🇹🇳TunisiaASTRA ZENECAexpiredFeb 1999
ZOLADEX
Implant / 3.6 MG
🇹🇳TunisiaASTRA ZENECAexpiredMay 1992
ZOLADEX
implant en seringue pré remplie / 3,6 mg
🇸🇳SenegalASTRA ZENECAactive
ZOLADEX
implant en seringue pré remplie / 10,8 mg
🇸🇳SenegalASTRA ZENECAactive
ZOLADEX 10.8 MG
IMPLANT INJECTABLE
🇲🇦Moroccoactive
ZOLADEX 3.6 MG
IMPLANT INJECTABLE
🇲🇦Moroccoactive

GOSERELINE in Africa — Regulatory Overview

GOSERELINE is registered across 4 African markets with 9 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Tunisia, Côte d'Ivoire, Morocco, Senegal. AfricaRegulatory refreshes this data daily from official government sources.

Of the 9 registrations, 6 (67%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.